心臓と肺のリハビリテーションのジャーナル

抽象的な

Utilizing Nanotechnology-Based Drug Delivery to Target Eosinophils in Chronic Respiratory Diseases

Payal Patel

Major chronic respiratory diseases (CRDs) include asthma, COPD, COVID-19, EGPA, lung cancer, and pneumonia. These diseases are responsible for a significant amount of morbidity and mortality and affect millions of people worldwide. These CRDs are diseases that can't be changed and affect different parts of the respiratory system. They have a big impact on people of all income levels. Eosinophils in the lungs have been linked to an increase in all of these CRDs. Eosinophils are essential immune mediators that play a role in the pathophysiology and homeostasis of various tissues. Interestingly, cellular processes that regulate airway hyper responsiveness, remodeling, mucus hyper secretion, and lung inflammation are linked to an elevated eosinophil level. In eosinophilmediated lung diseases, therefore, eosinophil is regarded as the therapeutic target. However, conventional treatments for CRDs include bronchodilators, antibiotics, and other anti-inflammatory medications. In any case, the improvement of protection from these remedial specialists after long haul utilization stays a test. However, recent advancements in nanotechnology have revealed the targeted nanocarrier approach, which has the potential to significantly enhance a therapeutic drug's pharmacokinetics. The nanocarrier system has the potential to specifically target eosinophils and the components that are associated with them in order to achieve promising results in the pharmacotherapy of CRDs.